Skip to main content

Table 2 Logistic regression analysis of parameters predicting overall [18F]PSMA-1007-PET/CT scan positivity: univariable analysis

From: Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer

Parameters Test Odds ratio (95% CIa); p value
Injected activity  + 1 unit 1 (0.99–1.01); 0.66
Interval injection-start scan  + 1 min 1.01 (0.99–1.04); 0.43
Neoadjuvant treatment Yes versus no 4.39 (0.61–31.75); 0.14
Primary treatment EBRTb versus RPc 3.52 (0.43–29.07); 0.24
Pathological primary tumour staging  + 1 stage 1.26 (0.53–3); 0.61
Pathological regional lymph node staging pN1 versus pN0 4.64 (0.89–24.16); 0.07
Positive surgical margin Global test p value = 0.43
Gleason score  + 1 level 1.2 (0.82–1.76); 0.35
Lymph nodes removed Yes versus no 0.38 (0.14–1.08); 0.07
Number lymph nodes removed  + 1 lymph node 1.02 (0.98–1.08); 0.33
Positive lymph nodes Yes versus no 3.96 (0.74–21.05); 0.11
PSA value RP  + 1 unit 4.96 (0.35–69.85); 0.24
Adjuvant EBRT Yes versus no 1.33 (0.43–4.18); 0.62
Prior ADTd Yes versus no 1.6 (0.64–4.02); 0.32
Ongoing ADT Yes versus no 2.16 (0.58–8.04); 0.25
Salvage therapy Yes versus no 0.63 (0.25–1.57); 0.32
PSA doubling time months  + 1 month 0.98 (0.94–1.02); 0.26
PSA velocity  + 1 unit 67.57 (1.56–2930.5); 0.03
PSA value  + 1 unit 1.58 (1.02–2.45); 0.04
  1. aConfidence interval
  2. bExternal beam radiation therapy
  3. cRadical prostatectomy
  4. dAndrogen deprivation therapy